Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
News|Articles|March 28, 2025
Hematologists Highlight Top Abstracts to Watch at the 2025 EBMT Annual Meeting
Author(s)Ashling Wahner
Fact checked by: Courtney Flaherty
Steven Devine, MD; Everett Meyer, MD, PhD; and Sophie Paczesny, MD, PhD, discuss their most highly anticipated presentations from the 2025 EBMT Meeting.
Advertisement
Advertisement
Ahead of the
Related to this article
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Advertisement
Advertisement